Published in Iran J Pharm Res on January 01, 2015
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods (1986) 12.51
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol (2009) 8.13
targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis. BMC Syst Biol (2008) 1.84
Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput Biol (2006) 1.53
Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis. Comput Biol Chem (2005) 1.52
Steady-state and pre-steady-state kinetic analysis of Mycobacterium tuberculosis pantothenate synthetase. Biochemistry (2001) 1.48
Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol (2000) 1.46
Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis (2010) 1.39
Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J Antimicrob Chemother (2007) 1.31
Ring-substituted imidazoles as a new class of anti-tuberculosis agents. Eur J Med Chem (2004) 1.30
Observing local and global properties of metabolic pathways: 'load points' and 'choke points' in the metabolic networks. Bioinformatics (2006) 1.26
Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact (2006) 1.26
New small-molecule synthetic antimycobacterials. Antimicrob Agents Chemother (2005) 1.23
Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew Chem Int Ed Engl (2009) 1.19
Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. Trends Microbiol (2010) 1.16
Synthesis and antitubercular screening of imidazole derivatives. Eur J Med Chem (2009) 1.15
A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J Biomol Screen (2006) 1.14
New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov Today (2006) 1.14
Inhibition of Mycobacterium tuberculosis pantothenate synthetase by analogues of the reaction intermediate. Chembiochem (2008) 1.05
The use of biodiversity as source of new chemical entities against defined molecular targets for treatment of malaria, tuberculosis, and T-cell mediated diseases--a review. Mem Inst Oswaldo Cruz (2005) 1.03
Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds. Bioorg Med Chem (2012) 1.03
Synthesis and Antimycobacterial Activity of Symmetric Thiocarbohydrazone Derivatives against Mycobacterium bovis BCG. Iran J Pharm Res (2013) 0.94
Protein interaction network analysis--approach for potential drug target identification in Mycobacterium tuberculosis. J Theor Biol (2009) 0.93
Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. J Am Chem Soc (2010) 0.91
Identification and characterization of potential therapeutic candidates in emerging human pathogen Mycobacterium abscessus: a novel hierarchical in silico approach. PLoS One (2013) 0.87
Identification and validation of novel drug targets in tuberculosis. Curr Pharm Des (2004) 0.87
The potential impact of structural genomics on tuberculosis drug discovery. Drug Discov Today (2006) 0.87
Synthesis and antitubercular activity of monocyclic nitroimidazoles: insights from econazole. Bioorg Med Chem Lett (2011) 0.86
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition. Bioorg Med Chem Lett (2011) 0.84
First novel anti-tuberculosis drug in 40 years. Nat Biotechnol (2013) 0.83
Fusing similarity rankings in ligand-based virtual screening. Comput Struct Biotechnol J (2013) 0.82
Attack on the scourge of tuberculosis: patented drug targets. Recent Pat Antiinfect Drug Discov (2006) 0.79
Screening for in vitro antimycobacterial activity and three-dimensional quantitative structure-activity relationship (3D-QSAR) study of 4-(arylamino)coumarin derivatives. Chem Biol Drug Des (2010) 0.79
Microwave-assisted solution-phase synthesis and DART-mass spectrometric monitoring of a combinatorial library of indolin-2,3-dione schiff bases with potential antimycobacterial activity. Molecules (2011) 0.78
Antitubercular activity of new coumarins. Chem Biol Drug Des (2011) 0.78
Synthesis and antimycobacterial activity of some phthalimide derivatives. Bioorg Med Chem (2012) 0.77
Evaluation of the Effect of PEGylated Single-Walled Carbon Nanotubes on Viability and Proliferation of Jurkat Cells. Iran J Pharm Res (2012) 0.77
Ligand-based virtual screening, parallel solution-phase and microwave-assisted synthesis as tools to identify and synthesize new inhibitors of mycobacterium tuberculosis. ChemMedChem (2006) 0.77
Antimycobacterial Activities of Novel 5-(1H-1,2,3-Triazolyl)Methyl Oxazolidinones. Tuberc Res Treat (2012) 0.77
Pharmacophore modeling and density functional theory analysis for a series of nitroimidazole compounds with antitubercular activity. Chem Biol Drug Des (2011) 0.77
The effect of indole derivatives on Mycobacterium tuberculosis. Experientia (1960) 0.76
Effect of lipophilic substituents on some biological properties of indoles. J Med Chem (1974) 0.76
Prenatal sex determination in suspicious cases of X-linked recessive diseases by the amelogenin gene. Iran J Basic Med Sci (2014) 0.75